drugset / Trial / NCT04629664
FX-322 in Adults With Severe Sensorineural Hearing Loss
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter, safety study of FX-322, administered by intratympanic injection, in adults with severe sensorineural hearing loss.
Timeline
- Start
- 2020-11-02
- Primary completion
- 2021-05-26
- Completion
- 2021-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | FX-322 | Unknown | — | Other |